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ABSTRACT 
Insulin is a hormone produced by pancreas that allows your body to utilize sugar (glucose) from carbohydrates in the 
food or to store glucose for future use. Successful Oral insulin delivery involves overcoming the enzymatic and 
physical barriers. Several companies across the globe are developing oral insulin based on different technology 
platforms. Insulin has been encapsulated in nanoparticles by muco-adhesive polymers such as chitosan, poly (lactic-co-
glycolic acid) (PLGA) and alginate which prevent enzymatic degradation, and allow absorption across the epithelial 
layer in Peyer’s patches.   
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Insulin
1
 
Insulin is a peptide hormone that allows your body to 
consume glucose. Insulin helps keep blood sugar level 
from getting too high (hyperglycemia) or too low 
(hypoglycemia). The cells in your body need sugar for 
energy. However, sugar cannot go into most of your 
cells directly. After you eat food and your blood sugar 
level rises, cells in your pancreas (known as beta cells) 
are signaled to release insulin into your bloodstream. 
Insulin then attaches to and signals cells to absorb sugar 
from the bloodstream. Insulin is often described as a 
“key,” which unlocks the cell to allow sugar to enter the 
cell and be used for energy. 
If you have more sugar in your body than it needs, 
insulin helps store the sugar in your liver and releases it 
when your blood sugar level is low or if you need more 
sugar, such as in between meals or during physical 
activity. Therefore, insulin helps balance out blood sugar 
levels and keeps them in a normal range. As blood sugar 
levels rise, the pancreas secretes more insulin. 
If your body does not produce enough insulin or your 
cells are resistant to the effects of insulin, you may 
develop hyperglycemia (high blood sugar), which can 
cause long-term complications if the blood sugar levels 
stay elevated for long periods of time. 
 
 
 
 
 
Structure of Insulin 
High-resolution model of six insulin molecules 
assembled in a hexamer, highlighting the threefold 
symmetry, the zinc ion holding it together (pink sphere), 
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and the histidine residues (pink sticks) involved in zinc 
binding. Inactive insulin is stored in the body as a 
hexamer, while the active form is the monomer 
 
 
 
Insulin Treatment for Diabetes
2
 
People with type 1 diabetes cannot make insulin because 
the beta cells in their pancreas are damaged or 
destroyed. Therefore, these people will need insulin 
injections to allow their body to process glucose and 
avoid complications from hyperglycemia. 
People with type 2 diabetes do not respond well or are 
resistant to insulin. They may need insulin shots to help 
them better process sugar and to prevent long-term 
complications from this disease. Persons with type 2 
diabetes may first be treated with oral medications, 
along with diet and exercise. Since type 2 diabetes is a 
progressive condition, the longer someone has it, the 
more likely they will require insulin to maintain blood 
sugar levels. 
Various types of insulin are used to treat diabetes and 
include
3, 4
 
 Rapid-acting insulin: It starts working 
approximately 15 minutes after injection and peaks 
at approximately 1 hour but continues to work for 
two to four hours. This is usually taken before a 
meal and in addition to a long-acting insulin. 
 Short-acting insulin: It starts working 
approximately 30 minutes after injection and peaks 
at approximately 2 to 3 hours but will continue to 
work for three to six hours. It is usually given 
before a meal and in addition to long-acting insulin. 
 Intermediate-acting insulin: It starts working 
approximately 2 to 4 hours after injection and peaks 
approximately 4 to 12 hours later and continues to 
work for 12-18 hours. It is usually taken twice a day 
and in addition to rapid- or short-acting insulin.  
 Long-acting insulin: It starts working after several 
hours after injection and works for approximately 
24 hours. If necessary, it is often used in 
combination with rapid- or short-acting insulin. 
Insulin can be given by a syringe, injection pen, or an 
insulin pump that delivers a continuous flow of insulin. 
 
Recent advances in insulin 
Researchers develop insulin substitute for 
treating diabetes orally.
5
 
Researchers from Australia's Curtin University have 
found an insulin substitute to treat diabetes orally. A 3D 
molecular map of insulin was used to identify the key 
features that are needed for insulin's activity. A lead 
drug molecule that fitted the map and mimicked insulin 
in specific biological assays and animal models was 
found. Unlike insulin, the small drug molecule isn't 
broken down in the stomach so can be taken orally as a 
tablet. The insulin substitute could potentially replace 
the need for injections for sufferers of both type 1 and 
type 2 diabetes, because type 1 diabetics depend on 
insulin for their survival, the researchers plan to initially 
target type 2 diabetics prior to them developing full 
insulin dependency. 
 
 Advantages
6
 
 Drug Delivery: it is a small, non-protein drug 
molecule for oral administration 
 Convenience: it is taken in tablet form 
 Safety: it circumvents the need for sterile needles 
 Cost: it is cheaper to synthesize 
 Ease of storage: it has a longer shelf life and does 
not require stringent, sterile conditions. 
 
Oral Insulin: The Rationale for This Approach and 
Current Developments. 
7
 
This review addresses the physiological advantages that 
may be derived from oral insulin administration and 
examines the various technologies at the forefront of 
oral insulin delivery. 
 
Current developments:  
 Several companies across the globe are developing 
oral insulin based on different technology platforms. 
Generic to all these efforts is a system that provides 
protection of the insulin while in transit in the 
gastrointestinal tract and which can take the form of 
physical encapsulation or the creation of a modified 
insulin resistant to degradation. 
 Tablet designed to release in duodenum: - In 
addition, some companies use an added component 
designed to enhance the transepithelial transport of 
the drug. Merrion Pharmaceuticals, a company 
based in Ireland, uses its GIPET
®
 platform to 
deliver macromolecules and polypeptides, including 
insulin. The GIPET system is based on promoting 
drug absorption through the use of matrices 
consisting of medium-chain fatty acids and 
formulated as solid dosage forms. The matrices 
enjoy food additive status (Generally Recognized as 
Safe, GRAS) and are normal dietary components 
with long records of safe use. Insulin and the other 
ingredients are prepared as a physical mix and are 
formulated into a tablet designed to be released in 
the duodenum.  
 Recombinant human insulin to withstand 
enzymatic degradation in the stomach and 
facilitate its absorption: - Biocon Limited, a 
biotechnology company located in India, is 
continuing the work of Nobex Corporation, 
developing oral insulin based on a modified form of 
insulin that possesses specific physicochemical 
characteristics that allow it to withstand enzymatic 
degradation in the stomach and facilitate its 
absorption. The conjugated insulin product (IN-105) 
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is recombinant human insulin conjugated covalently 
with a monodisperse, short-chain methoxy 
polyethylene glycol derivative that is crystallized 
and lyophilized into the dry active pharmaceutical 
ingredient after purification. An ascending dose 
study in type 2 diabetes has been presented. 
 Diasome, a U.S.-based company, is employing a 
hepatic-directed vesicle (HDV) for insulin delivery. 
A HDV consists of liposomes (≤150 nm diameter) 
encapsulating the insulin, which also contain a 
hepatocyte-targeting molecule in their lipid bilayer. 
The targeting molecule directs the delivery of the 
encapsulated insulin to the liver cells and therefore 
relatively minute amounts of insulin are required for 
effect.  
 Diabetology Limited, a U.K.-based company, is 
using its Axcess™ delivery technology system, 
which is based on a capsule containing a simple 
mixture of the drug, an absorption enhancer, and a 
solubilizer that allows absorption of the drug in the 
small intestine. The excipients used in the 
formulation are inert (GRAS) and are normal 
dietary components with long records of safe use. 
The company recently presented the results of a 
phase II, 10-day repeat-dose study of oral insulin in 
16 patients with type 2 diabetes. 
 Emisphere Technologies, a U.S.-based company, 
uses a system of carriers—designed low molecular 
weight chemical entities—that interact weakly and 
non-covalently with a protein drug. By altering the 
protein conformation and increasing its lipophilicity 
the carriers are able to enhance the transport of the 
protein across the gastrointestinal epithelium and 
into the bloodstream. 
 Oramed platform technology is based on 
components aimed at providing protection of the 
protein during passage through the gastrointestinal 
tract in combination with an absorption enhancer. 
Oramed's protectants and absorption enhancers 
consist of known pharmacopeia adjuvant with a 
long safety track record. Oramed has completed 
phase I trials in healthy volunteers; results have 
shown that oral insulin delivered with their system 
is safe, well tolerated, and consistently leads to a 
desired reduction in glucose and C-peptide.
8
 
 Of late, two other routes of insulin delivery 
systems—buccal and inhaled—are being advanced. 
Generex Biotechnology developed an oral–buccal 
insulin formulation whereby insulin is delivered 
directly into the mouth via a metered dose spray 
(RapidMist device, approved for use in Ecuador
9
). 
The insulin is not absorbed through the portal 
system but rather is systemic insulin. Generex's 
insulin has been approved and is available for 
clinical use in a few countries.  
MannKind cooperation has recently assumed the 
worldwide development and commercialization 
rights of Afrezzza (Human) inhaltion powder from 
Sanofi. 
 Coromed is a privately funded biotechnology 
company. Their flagship product is called Alveair, 
and offers a ‘needleless’ alternative for insulin 
users. The device delivers a regulated blast of 
insulin, and Coromed
10
 champion the fact that it has 
lower side-effect levels than injectable insulin. 
 Nektar formed from Inhale Therapeutic Systems 
Inc, is another company that is promising oral 
insulin. It has collaboration with pharmaceutical 
corporation Pfizer and Sanofi-Aventis. The Nektar 
Pulmonary delivery system is one facet they have 
developed. Exubera, fast-acting dry powder insulin 
designed for inhalation has been developed and is 
being reviewed.
11
 
 
Recent advances in oral insulin.12 
 Protecting insulin from enzymatic degradation by 
using antiproteolytic agents. 
 Promoting the gastrointestinal absorption of insulin 
through simultaneous use of a multitude of different 
penetration enhancers. 
 Chemical modification of insulin to improve its 
stability. 
 Bioadhesive delivery systems for enhancement of 
contact of the drug with the mucous membrane 
lining the gastrointestinal tract. 
 Carrier systems such micro spheres and 
nanoparticles which can improve the 
bioavailability-of insulin. 
 Peptidase Inhibitors: - Peptidase or protease 
inhibitors promote oral absorption of therapeutic 
peptides and proteins by reducing their proteolytic 
breakdown by enzymes in the gastrointestinal tract. 
Administration of insulin via microspheres together 
with the protease inhibitor aprotinin has been found 
to be the most efficacious combination involving 
protease inhibitors. 
 Chemical Modification:- Modifying the chemical 
structure of a peptide or protein is another approach 
to enhance its bioavailability by increasing its 
stability in the face of possible enzymatic 
degradation and/or its membrane permeation. A 
diacyl derivative of insulin has been seen to 
maintain its biological activity and also have 
increased absorption from the intestine. 
 
Oral insulin spray formulation and delivery 
system: 
13 
  
 The system allows a liquid oral spray insulin 
formulation to be delivered into the mouth 
(administered to the buccal mucosa using a 
proprietary delivery system) via an aerosolized 
spray.  
 The active pharmaceutical ingredient is recombinant 
human insulin; however, the formulation behaves in 
a fashion more similar to the synthetic fast-acting 
insulin analogues. One spray delivers approximately 
10 U of insulin to achieve absorption of 
approximately 1 U of insulin systemically.  
 The technology utilizes the formation of microfine 
micelles made from a combination of absorption 
enhancers that encapsulate and protect the insulin 
molecules for safe and effective delivery. The 
delivery device introduces a fine-particle aerosol at 
high velocity (100 mph; 160 km/h) into the 
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oropharyngeal cavity for local transmucosal 
absorption.  
 The manually actuated mechanism incorporated into 
the device introduces the dose and standardized 
volume of the insulin formulation in relation to the 
patient’s needs. Absorption is limited to the mouth 
with no entry of the product into the lungs. 
  Although a thin membrane in the buccal mucosa 
composed of many superficial blood vessels guards 
the large surface area in direct contact with the 
circulation, the impelled micelles transverse the 
buccal mucosa superficial layers, and with the aid of 
the absorption enhancers, insulin molecules get 
rapidly absorbed into the bloodstream and appear in 
the circulation within 5–10 min after administration. 
 
Cell penetrating peptide and silica-based 
nanoporous composites:14 
 Silica-based, mucoadhesive oral insulin formulation 
with encapsulated-insulin/cell penetrating peptide 
(CPP) to overcome both enzyme and mucosal 
barriers. 
 The CPPinsulin conjugates could facilitate cellular 
uptake of insulin while keeping insulin’s biologic 
functions intact. The low molecular weight 
protamine (LMWP) behaves like a CPP peptide.  
 The mucoadhesive properties of the produced silica-
chitosan composites can be controlled by varying 
both the pH and composition; the composite 
consisting of chitosan (25 wt-%) and silica (75 wt-
%) exhibited the greatest mucoadhesion at gastric 
pH.  
 Furthermore, drug release from the composite 
network could also be regulated by altering the 
chitosan content. Overall, the universal applicability 
of these technologies can lead to development of a 
generic platform for oral delivery of many other 
bioactive compounds, especially for peptide or 
protein drugs which inevitably encounter the poor 
bioavailability issues. 
 
Various approaches used in the 
development of oral insulin, and some of the 
recent data
 
related to novel oral insulin 
preparation.
15
 
 Insulin has been encapsulated in nanoparticles16 by 
muco-adhesive polymers such as chitosan, poly 
(lactic-co-glycolic acid) (PLGA),
17
 and 
alginate
18,19,20
 which prevent enzymatic degradation, 
and allow absorption across the epithelial layer in 
Peyer’s patches.21,22 
 Insulin has also been co-administered with protease 
inhibitors such as bacitracin, sodium glycocholate 
and camostat mesilate which improve the absorption 
rate.
23
 
 Insulin can also be modified by PEGylation, or by 
adding polyethylene glycol, which changes the 
pharmacokinetics, prevents enzymatic degradation, 
and increases absorption.
24
 
 An insulin analogue, IN-105, delivered orally in 
form of tablets has been modified by linking a 
single shortchain amphiphilic oligomer, through a 
covalent non-hydrolysable amide bond, to the free 
amino acid group on the Lys-b29 residue of 
recombinant human insulin. This improves its 
solubility, stability and systemic absorption. 
Solubility is increased by PEGylation, while 
stability may be due to stearic hindrance. IN-105 is 
rapid acting oral insulin which can potentially find 
place in control of post prandial hyperglycemia. It is 
presently being studied in a phase 3 trial in type 2 
diabetes, as well as a phase 1 trial in type 1 
diabetes.
25
 
 Another novel delivery mechanism is hepatic 
directed vesicles (HDV-I) loaded with insulin, 
which are <150 nm diameter liposomes that contain 
insulin attached a specific proprietary hepatocyte-
targeting molecule (HTM). HDV-1 is stable at low 
pH, in blood, is able to avoid enzymatic 
degradation, and has high biopotency, exhibited by 
its low dose of 5 U.
26
 
 Oral insulin in development for treatment of type 1 
and type 2 diabetes is ORMD-0801. Capsules of 
ORMD-0801 have 8 mg insulin each.
27
 
Nanospheres based oral insulin delivery: 
(Zinc insulin)
28 
 Zinc insulin is successfully encapsulated in various 
polyester and polyanhydride nanosphere 
formulations using Phase Inversion 
Nanoencapsulation (PIN). The encapsulated insulin 
maintains its biological activity and is released from 
the nanospheres over a span of approximately 6 h. A 
specific formulation, 1.6% zinc insulin in poly 
(lactide-co-glycolide) (PLGA) with fumaric 
anhydride oligimer and iron oxide additives has 
been shown to be active orally. 
 This formulation is shown to have 11.4% of the 
efficacy of intraperitoneally delivered zinc insulin 
and is able to control plasma glucose levels when 
faced with a simultaneously administered glucose 
challenge. A number of properties of this 
formulation, including size, release kinetics, 
bioadhesiveness and ability to traverse the 
gastrointestinal epithelium, are likely to contribute 
to its oral efficacy. 
Polylactide used to microcapsulate the 
insulin to avoid degradation by the enzymes 
in the GI.
29
 
 Polylactide was prepared in order to microcapsulate 
the insulin to avoid the enzymes in the 
GI.  Polylactide microcapsulated insulin (PLA-
MCI) when spherical in shape (diameter 1.5-2.0 
micron) the entrapment efficiency of insulin was 
90% and the loading rate was 10% (W/W). 
 PLA microcapsules are capable of protecting insulin 
from degradation by the proteolytic enzymes in the 
GI and of alleviating hyperglycemia for a prolonged 
period of time in diabetic rats. It may therefore be 
considered as a new carrier for oral insulin. 
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Oil-based formulations for oral delivery of 
Insulin: 
 Insulin was solubilized in the form of anhydrous 
reverse micelles. Process involved micellar 
dissolution of insulin followed by freeze drying, 
then reconstitution of lyophilized product with an 
oil phase. These formulations were stable at room 
temperature for up to 12 months. No significant 
changes in the appearance were observed and no 
degradation products of insulin were detected 
during the course of the stability study.  
 It was found that the efficacy of insulin oil solution 
(in diabetic/non diabetic rats) was dose dependent 
and insulin oil solution had the same efficacy as 
insulin emulsion with the same formulation 
composition. If ethylene-diaminetetraacetic acid 
(EDTA) was pre-delivered 40 min before the 
delivery of insulin oil solution, the hypoglycaemic 
effect of insulin oil solution was greatly enhanced, 
with an AUC (% glucose reduced) value increase 
from 28.5 ± 14.7 to 167.1 ± 72.3.  
 The improvement of oral absorption induced by pre-
delivery of EDTA might be attributed to enzyme 
inhibition, reduced gut mobility and the opening of 
paracellular routes.
30
 
 
Zonula Occludens Toxin (Zot)
31
 
 Aim of the study was to establish whether the 
permeabilizing effect of the toxin leads to increased 
intestinal absorption of macromolecules normally 
not absorbed when administered orally (insulin). 
 To evaluate the transepithelial transport of insulin 
10
-11
M alone or in the presence of 1.1×10
-10
M 
Zot, in vitro and in vivo experiments were 
performed on rabbit intestine. To evaluate the 
bioactivity of insulin after enteral co-administration 
with Zot, acute type 1 diabetic male BB/Wor rats 
were orally treated with insulin, with or without Zot, 
and the blood glucose levels of the rats were serially 
measured. Zot reversibly increases rabbit intestinal 
permeability to insulin by 72% (p=0.034) and 
immunoglobulins by 52% (p=0.04), in vitro. When 
tested in vivo, Zot induced a 10-fold increase of 
insulin absorption in both the rabbit jejunum and 
ileum, whereas no substantial changes were 
detected in the colon.  
 In diabetic rats, bioavailability of oral insulin co-
administered with Zot was sufficient to lower serum 
glucose concentrations to levels comparable to those 
obtained after parenteral injection of the hormone. 
The survival time of diabetic animals chronically 
treated with oral insulin+Zot was comparable to that 
observed in parenterally treated rats. This study 
offers a useful strategy for the oral delivery of drugs 
and proteins normally not absorbed through the gut. 
1. Depomed has no patents granted in India; only 1 
application is waiting for Examination 
(Acetaminophen). They have 2 products for Type 2 
diabetes (Metformin HCl & Sitagliptin Metformin 
HCl). 
2. EDTA chealates Mg, Ca invariably it acts as an 
inhibitor to the protein digesting enzymes, thus 
facilitating improvement of oral absorption [EDTA 
might be attributed to enzyme inhibition, reduced 
gut mobility and the opening of paracellular routes]. 
3. Solubilisation into the oil phase can avoid 
degradation of protein and the noncovalent coating 
of insulin molecules with lipophilic surfactant 
makes it possible to enhance permeation through the 
intestinal mucosa without introducing a new 
chemical entity.  
4. Trypsin is produced in the pancreas, serving a vital 
role in digestion by breaking down proteins into 
smaller molecules the body can use. It is transported 
from the pancreas to the small intestine where its 
function is optimized by the organ's slightly alkaline 
environment. 
Trypsin has an optimal operating pH of about 7-8 
(and reversibly inactivated at pH 4) and optimal 
operating temperature of about 37°C.
32
 The activity 
of trypsins is not affected by the inhibitor tosyl 
phenylalanyl chloromethyl ketone, TPCK, which 
deactivates chymotrypsin. 
Inhibitiors to prevent active trypsin are BPTI 
(bovine pancreatic trypsin inhibitor, or BPTI), 
SPINK1 (Pancreatic secretory trypsin inhibitor 
(PSTI) also known as serine protease inhibitor 
Kazal-type 1 (SPINK1) or tumor-associated trypsin 
inhibitor (TATI)) and α1-antitrypsin (Alpha-1 
Antitrypsin (A1AT)). Use of such inhibitors can be 
highly damaging. 
5. Trypsin is built with an extra piece of protein chain, 
this longer form of trypsin, called trypsinogen, is 
inactive and cannot cut protein chains. Then, when 
it enters the intestine, the enzyme enteropeptidase 
makes one cut in the trypsin chain, clipping off the 
little tail. This allows the new end of the chain to 
tuck into the folded protein and stabilize the active 
form of the enzyme. As extra insurance, the 
pancreas also makes a small protein, trypsin 
inhibitor that binds to any traces of active trypsin 
that might be present before it is secreted into the 
intestine. It binds to the active site of trypsin, 
blocking its action but not itself being cut into tiny 
pieces. 
6. Inhibitors bind strongly to trypsin, blocking its 
active site and instantly forming an irreversible 
compound and halting digestion of certain proteins. 
However, if trypsin inhibitors (specifically KTI) are 
present, the majority of trypsin in the cycle of 
digestion is inactivated and ingested proteins remain 
whole. Effects of this occurrence include gastric 
distress and pancreatic hyperplasia (proliferation of 
cells) or hypertrophy (enlargement of cells). 
7. In another separate experiment Influence of 
soybean-supplemented diet (naturally occurring 
purified trypsin inhibitors from soybean) on rat 
Pancreas and liver was conducted. This study 
demonstrated inhibition of growth in animals fed on 
trypsin inhibitor. The results of these experiments 
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confirm that the oral ingestion of raw soybean or 
purified trypsin inhibitors from varied sources is 
associated with enlargement of the pancreas in the 
rat (20% to 40% larger than normal) with an 
increased capacity to secrete pancreatic digestive 
enzymes. The liver was uninfluenced by the raw 
soybean diet.
33
 
Metal binding in Insulin 
34
 
 Zinc plays an important role in insulin 
hexamerisation, which is closely related to some of 
the processes in insulin biosynthesis and storage. 
 Zinc binds to insulin so that insulin is adequately 
stored in the pancreas and released when glucose 
enters the blood stream.
35
 
 Zinc plays a clear role in the synthesis, storage and 
secretion of insulin as well as conformational 
integrity of insulin in the hexameric form.
36
 
 
Zinc Insulin formulations. 
Human insulins currently on the market include rapid-
acting (Regular), intermediate acting 
(NPH and Lente) and long-acting (Ultralente) 
formulations. The former is a clear, colourless, aqueous 
solution buffered at neutral pH (7-7.8). Meta-cresol is 
added as preservative, glycerol as tonic stabiliser, as 
well as zinc chloride. Hexamers, made stable by zinc 
ions. 
Absorption of NPH is delayed by protamine, a protein 
extracted from the nucleus of fish sperm, where its role 
is to stabilise DNA. The commercial form is Isophane-
NPH insulin, a white suspension of orthorhombic 
crystals containing 0.9 molecules of protamine and two 
atoms of zinc per hexamer. In the crystal, protamine 
regulates interactions between dimers and hexamers. 
The vehicle is water buffered at pH 6.9-7.5. Phenol or 
metacresol are added as preservatives. Insulin crystals 
are insoluble in water and tend to precipitate to the 
bottom of the vial, which has to be tipped various times 
to resuspend them before use. NPH is longer-acting: in 
fact its blood absorption begins 1.5 h after subcutaneous 
injection; it has a peak plasma concentration at 4 to 12 h 
and disappears within 24 h. 
 
Effects if Proteolysis is hampered.
37
 
 Acidity is created through the digestion of protein. 
Therefore a protease deficiency results in an 
alkaline excess in the blood.  This alkaline 
environment can cause anxiety and insomnia.    
 In addition, since protein is required to carry 
protein-bound calcium in the blood, a protease 
deficiency lays the foundation for arthritis, 
osteoporosis and other calcium-deficient diseases.  
 Because protein is converted to glucose upon 
demand, inadequate protein digestion leads to 
hypoglycemia, resulting in moodiness, mood swings 
and irritability.  
 Protease also has an ability to digest unwanted 
debris in the blood including certain bacteria and 
viruses. Therefore, protease deficient people are 
immune compromised, making them susceptible to 
bacterial, viral and yeast infections and a general 
decrease in immunity. 
 
Oral Liposomes 
Issues Related to Oral Liposomes 
The problems associated with administering liposomes 
orally are as follows: 
1. Stability and Consistency: 
Liposomal formulations are vesicular systems which are 
suspended in physiological media. However, liposomal 
suspensions are highly unstable over longer duration of 
time (<3 weeks).  
Physical stability always poses a big issue in developing 
liposomal formulations for oral delivery. 
Remedy:  
a. Lyophilization of Liposomal suspension 
overcomes the physical instability of the system. 
The lyophilized liposomes are needed to be 
reconstituted with sterile water for oral delivery 
at the patient’s end. 
b. PROLIPOSOMES (Discussed in detail in 
ANNEXURE-I) 
2. GIT Physiological Barriers: 
a. Gastric pH: 
Liposomal formulations are susceptible to hydrolysis 
due to acidic pH of stomach. Lipids are more prone to 
acidic hydrolysis and hence the morphology of the 
liposomes gets distorted which then causes pre burst 
release of entrapped molecules. The un-buffered pH of 
the stomach ranges from 1.5 to 2.5 thus causing 
chemical instability in the liposome membrane surface. 
Remedy: 
a) Developing liposomes with acid stable lipids.38 
b) Microencapsulation of the prepared liposomes with 
polymers which are acid stable
39
 (Eg. Polyacrylates, 
polycarbophils, carbopol 934 etc.) 
b. Gastric and Intestinal Enzymes: 
Most of the lipids used in the preparation of 
Liposomes are esters of higher fatty acids including 
phospholipids viz. Phosphatidylcholines and 
phosphatidylethanolamines (soyalecithins-synthetic 
and non-synthetic sources). Gastric pepsins and 
intestinal trypsins and chymotrypsins are hydrolases 
which break lipid esters and dysfunctionalize 
liposomes into distorted structures. 
Lipases are prime hydrolases of lipids which are 
being secreted into small intestine. Lipases also 
cause hydrolytic degradation of liposomes. 
c. Bile acids : 
Bile acids are biosurfactants secreted from Gall bladder 
which are responsible for emulsifying lipophilic 
moieties reaching small intestine. Uncoated liposomes 
which are lipophilic in their surface characteristics are 
easily interacted by bile acids thereby causing 
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destabilization of vesicular structure of liposomes and 
premature expulsion of entrapped molecules. 
40,41
  
Hence, these released molecules are no longer protected 
and are thus exposed to luminal intestinal enzymes 
(hydrolases) causing their further degradation. 
Remedy: 
1. Incorporation of exogenous Bile salts in the 
developed liposomes (eg. Sod taurocholate, Sod 
glycocholate and Sod cholate) 
Bile salts used in the liposomes cater many significant 
advantages which are mentioned as under and then 
detailed in the ANNEXURE (ANX-I) 
a. Bile salts in the liposomes inhibit bile acid related 
destabilization of uncoated liposomes. 
b. Bile salts inhibits intestinal enzymes and thus 
enhances both liposomal and entrapped molecules’ 
stability, 
c. Bile salts acts as permeation enhancer for the 
liposomes and thus enhances transfection efficiency 
of the entrapped molecules throughout GIT into the 
blood stream. 
2. Coating of liposomes with hydrophilic polymers: 
Hydrophilic polymeric coating of liposomes decreases 
its proneness for interaction with bile acids in small 
intestine. 
A smart choice of polymers such as polyacrylates 
which are hydrophilic enteric polymers prevents 
both bile acid induced destabilization by providing 
hydrophilicity to the liposomal surface and further 
gives gastric pH protection to the surface of 
liposomes (being enteric releasing polymer). 
ANNEXURE-I 
1. Intracellular transfection of liposomes 
(permeation) through enterocytes. 
 
Pathways of drug absorption across the intestinal 
epithelium
42
 
2. Use of Liposomes To Aid Intestinal Absorption 
of Entrapped Insulin In Normal And Diabetic 
Dogs:
43
 
The effectiveness of liposomes in aiding intestinal 
absorption of entrapped insulin was studied in normal 
and diabetic dogs. lntraduodenal administration of free 
insulin (490 and 1630 U) or free insulin (88 U) plus 
empty liposomes to normal conscious dogs produced no 
change in plasma immunoreactive insulin or glucose. 
Administration of 40-80 U insulin entrapped in 
liposomes composed of either phosphatidylcholine, 
distearoylphosphatidylcholine, or dipalmitoyl-
phosphatidylcholine with cholesterol and dicetyl-
phosphate (in the ratio 10:2:1 by weight) to normal dogs 
produced substantial rises in peripheral plasma 
immunoreactive insulin after 45-60 min. However, the 
magnitude of these rises was neither reproducible nor 
dose-dependent. No fall in plasma glucose was 
observed, lntraduodenal administration of 50-100 U 
insulin entrapped in liposomes to diabetic dogs also 
produced rises in plasma immunoreactive insulin levels 
after 45-60 min but again these rises were not dose-
related. However, unlike the results in normal dogs, a 
small fall in plasma glucose followed the plasma 
immunoreactive insulin rise in diabetic dogs. This 
glucose fall was not dose-dependent nor was it related to 
the magnitude of the rise in plasma immunoreactive 
insulin.  
 
3. Oral delivery of insulin by using surface coating 
liposomes: Improvement in stability of insulin in 
GI tract.  
The potency of surface coated liposomes with some 
materials was investigated for oral delivery of peptide 
drugs. In vitro release of insulin, a model peptide, from 
liposomes in the bile salts solution was markedly 
reduced by coating the surface with the sugar chain 
portion of mucin (Mucin-Lip) or polyethylene glycol 
(PEG-Lip). Encapsulation of insulin into Mucin-Lip and 
PEG-Lip completely suppressed the degradation of 
insulin in the intestinal fluid, whereas uncoated 
liposomes suppressed it only partially. These results 
demonstrated that surface coating liposomes with PEG 
or mucin gained resistance against digestion by bile salts 
and increased the stability in the GI tract. Administration 
of insulin encapsulated in positively charged liposome 
caused the rapid decrease in the plasma glucose level 
which recovered to the control level within 3 h. In 
contrast, PEG-Lip and Mucin-Lip caused a gradual 
decrease in the glucose level after administration. The 
hypoglycemic effect by PEG-Lip lasted for much longer 
duration than that of uncoated liposomes. The slow 
release of insulin from the surface coating liposomes 
achieved the longer duration of oral hypoglycemic 
activity.
44
 
4. Enhanced oral absorption of insulin-loaded 
liposomes containing bile salts: A mechanistic 
study: 
A bile salt-reinforced liposome (BS-liposomes) system 
composed of soybean phosphatidylcholine and three 
types of bile salts (sodium glycocholate, sodium 
taurocholate and sodium deoxycholate) was developed 
for the oral delivery of insulin. The prepared BS-
liposomes showed good protection of insulin against 
enzymatic degradation by pepsin, trypsin and 
chymotrypsin in vitro and a sustained hypoglycemic 
effect for 24 h with oral bioavailability of 10.2% in 
diabetic rats. Some studies in the field of oral 
vaccination
45
 revealed that incorporation of bile salt in 
liposomal formulation could stabilize the membrane 
against the detrimental effects of bile acids in the 
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gastrointestinal tract (GIT)
46
. Besides, the presence of 
bile salts possibly enhances the internalization of BS-
liposomes due to their absorption-enhancing effect. 
5. Hypoglycemic activity and oral bioavailability of 
insulin-loaded liposomes containing bile salts in 
rats: The effect of cholate type, particle size and 
administered dose:
47
 
The addition of bile salts to the lipid bilayers of the 
liposomes was believed to make the vehicles resistant to 
the detrimental effects of physiological bile salts in the 
GI tract and thus protect entrapped molecules from 
enzymatic degradation. Furthermore, bile salts 
embedded in the lipid bilayers of liposomes may 
perform membrane-destabilizing effect upon contact 
with the intestinal epithelia and facilitate internalization 
of the particles. A pro-liposome formulation of 
bilosomes (bile salt containing liposomes) has shown 
preliminary enhancing effect on oral bioavailability of a 
model peptide drug salmon calcitonin.
48,49
  Oral 
administration of these liposomes elicited mild and 
prolonged hypoglycemic effect in parallel with increase 
in blood insulin levels for a duration of over 20 h, 
peaking at about 8–12 h. Mechanistic study supports 
absorption of intact liposomes that encapsulate 
(Recombinant) rhINS rather than free rhINS. The 
hypoglycemic effect and oral bioavailability of the 
liposomes containing either bile salts or cholesterol were 
in the order of SGC > STC > CH > SDC, which is 
attributable to the better protective effect on 
encapsulated rhINS against enzymatic degradation. The 
highest oral bioavailability of 8.5% and 11.0% can be 
achieved by SGC-liposomes in non-diabetic and diabetic 
rats, respectively.  
6. Liposomes containing Sodium glycocholate 
(SGC) as potential oral insulin delivery system: 
preparation, in vitro characterization, and 
improved protection against enzymatic 
degradation. 
The optimal formulation showed an insulin entrapment 
efficiency of 30% ± 2% and a particle size of 154 ± 18 
nm. Transmission electron micrographs revealed a 
nearly spherical and deformed structure with discernable 
lamella or sodium glycocholate  liposomes.  Sodium 
glycocholate  liposomes  showed  better  protection  of  
insulin  against  enzymatic  degradation  by  pepsin,  
trypsin and α-chymotrypsin than liposomes containing 
the bile salt counterparts of sodium taurocholate  and 
sodium deoxycholate. 
Proliposomes
50
 
For liposomes to enter the market, they must be stable 
during the storage period, and remain intact before 
reaching their targeted tissues to produce action. Various 
approaches have been used to overcome these problems, 
some of which include control of particle size and 
lamellarity, altering the lipid composition, electrostearic 
stabilization and lyophilization etc. Lyophilization is 
the only technique which produces liposomes with long 
term stability profile.  
One of approaches which helped in overcoming the 
stability issue associated with liposome and led to the 
development of a new drug delivery system is the 
Proliposome (PL).  
Proliposomes (PLs) are dry, free-flowing granular 
products composed of drug(s) and phospholipid(s) 
which upon addition of water, disperse to form a multi-
lamellar liposomal suspension. It is one of the most cost-
effective and widely used methods for producing 
commercial liposome products. It is based upon the 
intrinsic property of hydrated membrane lipids to form 
vesicles on contact with water. Being available in dry 
powder form, they are easy to distribute, transfer, 
measure and store making it a versatile system. 
Liposomes can either be formed in vivo under the 
influence of physiological fluids or can be formed in 
vitro prior to administration using a suitable hydrating 
fluid. The liposomes formed on reconstitution are 
similar to conventional liposomes and more uniform in 
size. 
51, 52 
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